Related Experiment Video
Updated: Mar 15, 2026
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
"Hep C, where art thou": What are the remaining (fundable) questions in hepatitis C virus research?
1Division of Gastroenterology and Hepatology (B-158), Department of Medicine, University of Colorado Health Sciences Center, Aurora, CO.
Insights
Hepatitis C virus (HCV) eradication is not complete, as many infected individuals remain unaware of their condition. Continued research is vital for addressing residual risks and developing new strategies for HCV elimination.
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Background:
- Hepatitis C virus (HCV) cure represents a major medical advancement, but eradication efforts are ongoing.
- Many HCV-infected individuals are unaware of their status, posing risks for transmission and disease progression.
- Simple treatments are insufficient for eradicating infections, as exemplified by syphilis.
Purpose of the Study:
- To highlight that Hepatitis C virus (HCV) eradication is incomplete.
- To discuss complex, unresolved issues in HCV research and management.
- To provide a perspective on critical areas for future HCV investigation.
Main Methods:
- Perspective piece based on current scientific understanding and clinical experience.
- Discussion of existing literature and future research directions.
- Identification of key challenges in achieving HCV eradication.
Main Results:
- HCV eradication is far from accomplished despite effective treatments.
- Unawareness of infection and residual disease progression are significant concerns.
- Complex questions remain regarding DAA failures, vaccine prospects, and antibody applications.
Conclusions:
- Continued research and strategic interventions are essential for HCV eradication.
- Addressing unawareness, transmission, and long-term risks is crucial.
- Future efforts should focus on optimizing DAA strategies, vaccine development, and novel therapeutic approaches.
Abstract:
Hepatitis C virus (HCV) has dominated the field of hepatology for the past 25 years, and its cure in the majority of treated patients is one of the greatest achievements in all of medicine. However, the latter has led to the belief by some that HCV research should be shelved for other, more pressing areas. The mission for HCV eradication is far from accomplished. As a historical reference, we should consider that disease elimination has required vaccination with all previously controlled infections including smallpox and polio and that simple, effective treatment is not sufficient in most infections to lead to substantial control. Syphilis is the best example, for which a single dose of penicillin (which literally costs pennies and that we have had since 1945) is curative in early stages. Not only have we not eradicated syphilis, rates of infection have increased in many places within the United States in recent years. Most HCV-infected subjects are unaware of their infection, remaining at risk for transmission to others and disease progression, including cirrhosis and hepatocellular carcinoma. In the era of highly effective direct-acting antivirals (DAAs), many questions pertaining to HCV remain, but they are more complex and difficult to answer. Here, I provide my perspective on some of these salient issues: the residual risk for disease progression after sustained virologic response, the optimal approach to current DAA failures, the impact of targeting people who inject drugs with DAAs, vaccine prospects, and application of neutralizing HCV glycoprotein antibodies. (Hepatology 2017;65:341-349).
